GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults – Nasdaq

GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq
BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered …
GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adultsPharmaceutical Business Review
GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With MarketWatch

all 7 news articles »

View full post on asthma – Google News

GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults – RTT News

GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults
RTT News
GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease.
GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With MarketWatch

all 4 news articles »

View full post on asthma – Google News

Professional Medical Center Launches New Initiative to Help Diagnose Adults … – Michronicleonline


Michronicleonline

Professional Medical Center Launches New Initiative to Help Diagnose Adults
Michronicleonline
Launched earlier this year, the Professional Medical Center Asthma Project invites any resident living in Oakland or Wayne County suffering from asthma or allergy symptoms to take the ImmunoCAP test. The test can be administered at any one of …

View full post on asthma – Google News

UPDATE 1-FDA panel backs approval of GSK asthma drug in adults – Reuters


MedPage Today

UPDATE 1-FDA panel backs approval of GSK asthma drug in adults
Reuters
If approved, the drug would be marketed under the trade name Nucala and be the first new biologic treatment for severe asthma in more than a decade. Asthma affects more than 22 million people in the United States. Severe asthma accounts for 5 to 10 …
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in StreetInsider.com
Asthma Drug Targeting IL-5 Wins Partial Backing From FDA AdvisersMedPage Today
FDA committee recommends approval of Nucala for adults with severe asthmaHealio
Reuters India
all 12 news articles »

View full post on asthma – Google News